PIRS Pieris Pharmaceuticals Inc.

2.92
+0.03  (+1%)
Previous Close 2.89
Open 2.9
Price To Book 3.6
Market Cap 143521559
Shares 49,151,219
Volume 79,522
Short Ratio
Av. Daily Volume 354,899

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 1H 2019.
PRS-080
Anemia of chronic disease
Phase 1 initial data due at ATS meeting May 22, 2019 1:30pm.
PRS-060
Healthy subjects
Phase 1 data due 2019.
PRS-343
HER2-positive solid tumors
Phase 1 data due 2019.
PRS-343 and atezolizumab (Tecentriq)
HER2-positive solid tumors

Latest News

  1. Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
  2. Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  3. Edited Transcript of PIRS earnings conference call or presentation 12-Mar-19 12:00pm GMT
  4. Pieris Pharmaceuticals Reports 2018 Year-End Cash Position and Provides Corporate Update
  5. Pieris Pharmaceuticals, Inc. to Host Earnings Call
  6. Pieris Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
  7. Pieris Pharmaceuticals to Host Full-Year 2018 Investor Call and Corporate Update on March 12, 2019
  8. Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasizes Economic Growth
  9. Does Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Have A Particularly Volatile Share Price?
  10. What Kind Of Shareholder Appears On The Pieris Pharmaceuticals, Inc.’s (NASDAQ:PIRS) Shareholder Register?
  11. These 4 Pharma Stocks Could Test December Highs
  12. Should You Buy Pieris Pharmaceuticals, Inc. (PIRS)?
  13. How Much Did Pieris Pharmaceuticals Inc’s (NASDAQ:PIRS) CEO Pocket Last Year?
  14. New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  15. Edited Transcript of PIRS earnings conference call or presentation 7-Nov-18 1:00pm GMT
  16. P.A.W. Capital Partners’ Returns, AUM, and Holdings
  17. Pieris Pharmaceuticals to Present at Investor Conferences in November
  18. Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
  19. Pieris Pharmaceuticals: 3Q Earnings Snapshot
  20. Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update